This study examines urine samples to find new DNA markers (called biomarkers) for detection of upper tract urothelial cancer and to better understand how to treat patients with upper tract urothelial cancer.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT06805630.
Locations matching your search criteria
United States
North Carolina
Durham
Duke University Medical CenterStatus: Active
Contact: Michael Abern
Phone: 919-684-2443
PRIMARY OBJECTIVES:
I. To validate previously determined thresholds of urine methylation biomarkers in patients with known UTUC compared to healthy controls in a large multicenter study.
II. To determine the relationship between the urine methylation markers and clinical features, including pathologic stage and grade, in patients undergoing extirpative surgery.
III. To determine the levels of methylation biomarkers in the urine of patients with UTUC after surgery compared to preoperative thresholds.
OUTLINE: This is an observational study.
Patients undergo urine specimen collection and have their medical records reviewed throughout the study.
Trial PhaseNo phase specified
Trial TypeNot provided by clinicaltrials.gov
Lead OrganizationDuke University Medical Center
Principal InvestigatorMichael Abern
